On January 17, 2024, the company announced that it has extended its plan duration till June 30, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 USD | +1.43% |
|
+6.77% | -47.41% |
Jun. 30 | Enlivex Therapeutics Ltd.'s Equity Buyback announced on August 30, 2023 has expired. | CI |
Jun. 24 | Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.41% | 29.22M | |
+20.95% | 127B | |
+23.00% | 116B | |
+25.15% | 27.69B | |
-19.75% | 19.62B | |
-16.57% | 16.26B | |
-16.56% | 15.49B | |
+11.19% | 14.81B | |
-46.65% | 14.39B | |
+57.74% | 14.11B |
- Stock Market
- Equities
- ENLV Stock
- News Enlivex Therapeutics Ltd.
- Enlivex Therapeutics Ltd.'s Equity Buyback Plan Extended till June 30, 2024.